Peter G. Jenner

Q: What Schools Are Affiliated With Peter G. Jenner

Peter G. Jenner is affiliated with the following schools: King's College London, King's College, Aberdeen, University of Lausanne

Peter G. Jenner's AcademicInfluence.com Rankings

Peter G. Jenner

Biology

#2935

World Rank

#4571

Historical Rank

Neuroscience

#258

World Rank

#272

Historical Rank

Biochemistry

#248

World Rank

#310

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Peter G. Jenner Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Peter G. Jenner's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE (1989) (1697)
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia (1994) (1093)
Oxidative stress and the pathogenesis of Parkinson's disease (1996) (980)
Non-motor features of Parkinson disease (2017) (965)
Oxidative stress in Parkinson's disease (2003) (837)
Understanding cell death in parkinson's disease (1998) (684)
Proteasomal function is impaired in substantia nigra in Parkinson's disease (2001) (629)
Altered Proteasomal Function in Sporadic Parkinson's Disease (2003) (597)
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease (2011) (594)
Parkinson disease: from pathology to molecular disease mechanisms. (2013) (544)
Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease (1992) (542)
A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease (1997) (531)
Failure of the ubiquitin–proteasome system in Parkinson's disease (2001) (530)
Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study (1994) (425)
In‐vitro Inhibition of Human Erythrocyte Acetylcholinesterase by Salvia lavandulaefolia Essential Oil and Constituent Terpenes (2000) (421)
The pathogenesis of cell death in Parkinson's disease (2006) (414)
The pathophysiology of extrapyramidal side-effects of neuroleptic drugs (1980) (413)
Levodopa in the treatment of Parkinson's disease: Current controversies (2004) (370)
Adenosine A2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys (1998) (367)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset (1984) (328)
Impairment of the ubiquitin‐proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures (2002) (321)
Oxidative mechanisms in nigral cell death in Parkinson's disease. (1998) (317)
Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease (1994) (315)
Novel pharmacological targets for the treatment of Parkinson's disease (2006) (304)
Glutathione‐related enzymes in brain in Parkinson's disease (1994) (295)
New insights into the cause of Parkinson's disease (1992) (282)
Aggresome‐related biogenesis of Lewy bodies (2002) (281)
Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease (2005) (276)
Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia (1992) (272)
Proteasome inhibition causes nigral degeneration with inclusion bodies in rats (2002) (266)
Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. (1997) (261)
Etiology and pathogenesis of Parkinson's disease (2011) (261)
Non motor subtypes and Parkinson's disease. (2016) (256)
Combined Use of the Adenosine A2A Antagonist KW-6002 with l -DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys (2000) (249)
Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration (2002) (247)
Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease). (2014) (235)
De novo administration of ropinirole and bromocriptine induces less dyskinesia than L‐dopa in the MPTP‐treated marmoset (1998) (230)
Selective loss of 20S proteasome α-subunits in the substantia nigra pars compacta in Parkinson's disease (2002) (224)
Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus) (1995) (219)
Molecular mechanisms of L-DOPA-induced dyskinesia (2008) (216)
Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam. (1977) (214)
Oxidative stress as a cause of Parkinson's disease (1991) (211)
Oxidative stress as a cause of Parkinson's disease (1991) (211)
Parkinson's disease, pesticides and mitochondrial dysfunction (2001) (181)
Increased cannabinoid CB1 receptor binding and activation of GTP‐binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP‐treated marmosets (2001) (176)
Adenosine, adenosine A 2A antagonists, and Parkinson's disease. (2009) (173)
Non-motor features of Parkinson disease (2017) (170)
Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected (2014) (168)
Pathogenesis of Parkinson's disease (2013) (168)
The substituted benzamides--a novel class of dopamine antagonists. (1979) (161)
Time course of inhibition of brain nitric oxide synthase by 7-nitro indazole. (1994) (157)
Metoclopramide and dopamine receptor blockade (1976) (157)
In‐vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's disease (2001) (154)
Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease (1993) (152)
A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. (1992) (149)
Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease (2005) (147)
Changes in dopamine-mediated behaviour during one year's neuroleptic administration. (1979) (144)
The role of D-1 and D-2 receptors (1980) (138)
Adenosine A2A receptors and Parkinson's disease. (2009) (134)
Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease (1991) (131)
Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease (2003) (131)
Suppressive effect of L‐dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6‐hydroxydopamine (1993) (130)
Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration. (1980) (130)
Altered Glial Function Causes Neuronal Death and Increases Neuronal Susceptibility to 1‐Methyl‐4‐Phenylpyridinium‐ and 6‐Hydroxydopamine‐Induced Toxicity in Astrocytic/Ventral Mesencephalic Co‐Cultures (1999) (129)
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates (2005) (128)
Substituted benzamides as cerebral dopamine antagonists in rodents (1977) (128)
Altered Muscarinic and Nicotinic Receptor Densities in Cortical and Subcortical Brain Regions in Parkinson's Disease (1993) (127)
Substituted benzamide drugs as selective neuroleptic agents. (1981) (126)
A comparison of in vitro and in vivo dopamine receptor antagonism produced by substituted benzamide drugs (1978) (123)
The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. (2003) (122)
Striatal dopamine receptors become supersensitive while rats are given trifluoperazine for six months (1979) (122)
The acute and the long‐term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation (2005) (121)
What has been learnt from study of dopamine receptors in Parkinson's disease? (2006) (121)
The rationale for the use of dopamine agonists in Parkinson's disease (1995) (120)
L-Dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations (2001) (114)
Acute dystonia induced by neuroleptic drugs (2004) (113)
The effect of chronic neuroleptic administration on cerebral dopamine receptor function. (1983) (113)
The MPTP-treated primate as a model of motor complications in PD (2003) (113)
Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. (1980) (112)
The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset (1985) (112)
In 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Primates, the Selective 5-Hydroxytryptamine 1a Agonist (R)-(+)-8-OHDPAT Inhibits Levodopa-Induced Dyskinesia but Only with\ Increased Motor Disability (2006) (111)
Alterations in preproenkephalin and adenosine‐2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with l‐DOPA (2000) (110)
Oxidative stress in Parkinson's disease and other neurodegenerative disorders. (1996) (109)
3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates (2003) (109)
Cation regulation differentiates specific binding of [3 H]sulpiride and [3 H]spiperone to rat striatal preparations (1980) (108)
Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones. (1984) (108)
Functional models of Parkinson's disease: A valuable tool in the development of novel therapies (2008) (107)
Proteasomal activity in brain differs between species and brain regions and changes with age (2005) (106)
The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II (2007) (106)
High affinity binding of [3H] (−)-nicotine to rat brain membranes and its inhibition by analogues of nicotine (1988) (104)
Dopamine agonists and neuroprotection in parkinson's disease (1998) (103)
Oxidative Stress and Parkinson's Disease a (1996) (103)
Adenosine A2A receptors modify motor function in MPTP‐treated common marmosets (1998) (103)
Increased striatal dopamine efflux in vivo following inhibition of cerebral nitric oxide synthase by the novel monosodium salt of 7‐nitro indazole (1995) (102)
Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain (2003) (102)
A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD (2003) (102)
Pramipexole protects against apoptotic cell death by non‐dopaminergic mechanisms (2004) (101)
Levodopa in the treatment of Parkinson’s disease (2009) (98)
A novel dopamine agonist for the transdermal treatment of Parkinson’s disease (2005) (96)
Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. (1980) (96)
Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. (1985) (95)
Superoxide‐dependent depletion of reduced glutathione by L‐DOPA and dopamine. Relevance to Parkinson's disease (1995) (95)
Altered 5‐HT metabolism with clonazepam, diazepam and diphenylhydantoin (1975) (94)
Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease (2004) (93)
P450 enzymes and Parkinson's disease: The story so far (1998) (93)
Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets (2002) (92)
When Do Levodopa Motor Fluctuations First Appear in Parkinson’s Disease? (2010) (90)
Antiparkinsonian activity and dyskinesia risk of ropinirole and L‐DOPA combination therapy in drug naive MPTP‐lesioned common marmosets (Callithrix jacchus) (2001) (88)
Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease. (1983) (88)
Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure (2003) (88)
Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism (2003) (88)
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. (1986) (87)
Specific binding of [3H]sulpiride to rat striatal preparations (1979) (86)
Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. (1993) (86)
An immunohistochemical study of the acute and long-term effects of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in the marmoset (1987) (86)
Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors. (1983) (85)
Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. (2000) (84)
Parkinson’s Disease – the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis (2014) (83)
Pharmacology of dopamine agonists in the treatment of Parkinson’s disease (2002) (83)
MANIPULATION OF BRAIN SEROTONIN IN THE TREATMENT OF MYOCLONUS (1975) (83)
Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. (2019) (82)
Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT‐PCR (2003) (82)
Pramipexole protects against MPTP toxicity in non‐human primates (2006) (81)
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation (2011) (81)
A behavioural and biochemical comparison of dopamine receptor blockade produced by haloperidol with that produced by substituted benzamide drugs. (1978) (79)
Age-associated changes in protein oxidation and proteasome activities in rat brain: modulation by antioxidants. (2005) (79)
Antidepressant-like activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents (2013) (78)
Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats (2006) (78)
L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. (1995) (78)
The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I (2007) (75)
Neurodegeneration and Neuroprotection in Parkinson's Disease (1996) (74)
Alterations in striatal and extrastriatal D‐1 and D‐2 dopamine receptors in the MPTP‐treated common marmoset: An autoradiographic study (1993) (74)
A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets (2005) (74)
Chronic l-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats (1999) (73)
Both Short- and Long-Acting D-1/D-2 Dopamine Agonists Induce Less Dyskinesia than l-DOPA in the MPTP-Lesioned Common Marmoset (Callithrix jacchus) (2003) (72)
Chronicl-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat (1995) (72)
Avoidance of dyskinesia (2004) (70)
α‐tocopherol levels in brain are not altered in Parkinson's disease (1992) (70)
Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia (2010) (70)
Kainic acid lesions of striatum and decortication reduce specific [3H]sulpiride binding in rats, so D‐2 receptors exist post‐synaptically on corticostriate afferents and striatal neurons (1981) (70)
Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of parkinson's disease patients (1994) (69)
An overview of adenosine A2A receptor antagonists in Parkinson's disease. (2014) (69)
Striatal plasticity in Parkinson's disease and L-dopa induced dyskinesia. (2012) (68)
Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? (2006) (68)
The roles of noradrenaline and dopamine in contraversive circling behaviour seen after unilateral electrolytic lesions of the locus coeruleus. (1976) (67)
beta-Adrenoreceptor antagonists in essential tremor. (1979) (67)
The effect ofl-DOPA and carbidopa treatment on the survival of rat fetal dopamine grafts assessed by tyrosine hydroxylase immunohistochemistry and [3H]mazindol autoradiography (1991) (67)
Perspectives on recent advances in the understanding and treatment of Parkinson’s disease (2009) (67)
AMINES, ANTICONVULSANTS, AND EPILEPSY (1975) (67)
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson’s disease (2004) (67)
Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration (1996) (67)
Dopamine, but Not Norepinephrine or Serotonin, Reuptake Inhibition Reverses Motor Deficits in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Primates (2002) (66)
ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease. (1996) (66)
Differential anatomical location of [3H]‐N,n‐propylnorapomorphine and [3 H]‐spiperone binding sites in the striatum and substantia nigra of the rat (1983) (66)
L‐Dopa Methyl Ester—A Candidate for Chronic Systemic Delivery of L‐Dopa in Parkinson's Disease (1984) (65)
Chronic pharmacological manipulation of dopamine receptors in brain (1987) (65)
Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. (1993) (65)
Chronic clozapine treatment of rats down-regulates cortical 5-HT2 receptors. (1983) (65)
High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5 (1998) (64)
Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities (2008) (64)
The effect of chronic l-DOPA treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts (1991) (63)
Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset (2000) (62)
Apomorphine - pharmacological properties and clinical trials in Parkinson's disease. (2016) (61)
Autoradiographic study of striatal D1 and D2 dopamine receptors in 6-OHDA-lesioned rats receiving foetal ventral mesencephalic grafts and chronic treatment withl-DOPA and carbidopa (1992) (61)
The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. (2006) (60)
Dopamine D1 receptor expression in human basal ganglia and changes in Parkinson's disease (2001) (60)
Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex (2013) (60)
Indices of oxidative stress in Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies. (1997) (60)
Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (1988) (58)
Induction of purposeless chewing behaviour in rats by 5-HT agonist drugs. (1989) (58)
From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease. (2009) (58)
Antiparkinsonian activity of CY 208–243, a partial D‐1 dopamine receptor agonist, in MPTP‐treated marmosets and patients with Parkinson's disease (1989) (57)
The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. (1988) (57)
Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets. (2001) (57)
Stimulation of adenylate cyclase activity by benzazepine D-1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat--relationship to circling behaviour. (1995) (56)
The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset (1988) (56)
Evidence that [3H]Dopamine Is Taken Up and Released from Nondopaminergic Nerve Terminals in the Rat Substantia Nigra In Vitro (1985) (56)
Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease (2006) (55)
effect of unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway on GABAA receptor subunit gene expression in the rodent basal ganglia and thalamus (1999) (55)
Pharmacological characterisation of spontaneous or drug-associated purposeless chewing movements in rats (2004) (55)
Comparison of the In‐vitro Receptor Selectivity of Substituted Benzamide Drugs for Brain Neurotransmitter Receptors (1988) (55)
L‐Dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease ‡ (1987) (55)
Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT. (1986) (54)
GDNF reverses priming for dyskinesia in MPTP‐treated, l‐DOPA‐primed common marmosets (2001) (54)
Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats (2014) (54)
Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. (1992) (53)
Effect of metoclopramide on turnover of brain dopamine noradrenaline and 5‐hydroxytryptamine * (1975) (53)
Clues to the mechanism underlying dopamine cell death in Parkinson's disease. (1989) (53)
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats (2007) (52)
Relationship between plasma propranolol concentration and relief of essential tremor. (1979) (52)
Serotonin metabolism in human epiepsy: The influence of anticonvulsant drugs (1977) (52)
Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments (2000) (52)
Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline (2011) (52)
A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy (2010) (51)
Relationship between animal models and clinical parkinsonism. (1975) (51)
Behavioural and immunohistochemical changes following supranigral administration of sonic hedgehog in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets (2002) (51)
Levodopa neurotoxicity (1998) (51)
Effects of 6-hydroxydopamine lesions of the nigrostriatal pathway on striatal serotonin innervation in adult rats (1991) (51)
Clonazepam induces decreased serotoninergic activity in the mouse brain (1979) (51)
Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets (2004) (51)
Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future (2016) (51)
D3 receptor expression within the basal ganglia is not affected by Parkinson's disease (1996) (50)
Switching from Levodopa to the Long-acting Dopamine D2/D3 Agonist Piribedil Reduces the Expression of Dyskinesia While Maintaining Effective Motor Activity in MPTP-treated Primates (2006) (50)
Cholinergic manipulation of perioral behaviour induced by chronic neuroleptic administration to rats (2004) (50)
Intraventricular infusion of basic fibroblast growth factor (bFGF) in the MPTP‐treated common marmoset (1996) (50)
S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole (2004) (50)
Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437. (1989) (50)
Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease. (1996) (50)
AMINES, ANTICONVULSANTS, AND EPILEPSY (1975) (50)
Nigral dopaminergic cell loss in vitamin E deficient rats. (1994) (49)
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. (2003) (49)
Lipopolysaccharide-induced nigral inflammation leads to increased IL-1β tissue content and expression of astrocytic glial cell line-derived neurotrophic factor (2012) (49)
Effects of opioid agonist drugs on the in vitro release of 3H-GABA, 3H-dopamine and 3H-5HT from slices of rat globus pallidus. (1987) (49)
Continuous drug delivery in early- and late-stage Parkinson’s disease as a strategy for avoiding dyskinesia induction and expression (2011) (48)
Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys (2002) (48)
Are dopamine receptors present on human lymphocytes? (1982) (48)
Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data. (1986) (48)
Lipophilicity Plays a Major Role in Modulating the Inhibition of Monoamine Oxidase B by 7‐Substituted Coumarins (2006) (48)
Effect of Experimental Ischemia on Neurotransmitter Amines in the Gerbil Brain (1979) (47)
Repeated administration of piribedil induces less dyskinesia than L‐dopa in MPTP‐treated common marmosets: A behavioural and biochemical investigation (2002) (47)
Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. (2009) (47)
Comparison of the effects of benzodiazepines and other anticonvulsant drugs on synthesis and utilization of 5-ht in mouse brain (1985) (46)
Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease. (2003) (46)
Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets (2007) (45)
Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction (2009) (45)
Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration (2005) (45)
Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets (1999) (45)
The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP‐treated and levodopa‐primed common marmosets (2002) (45)
Chronic continuous administration of neuroleptic drugs alters cerebral dopamine receptors and increases spontaneous dopaminergic action in the striatum (1982) (45)
Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets. (1989) (44)
Striatal neuropeptide levels in Parkinson's disease patients (1992) (44)
Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin (1989) (44)
Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP‐treated common marmosets (2005) (43)
Turning behaviour induced by injection of muscimol or picrotoxin into the substantia nigra demonstrates dual GABA components (1979) (43)
Anticonvulsant drugs alter plasma tryptophan concentrations in epileptic patients: implications for antiepileptic action and mental function. (1984) (42)
Neuroleptic‐induced acute dystonic reactions may be due to enhanced dopamine release on to supersensitive postsynaptic receptors (1981) (42)
Treatment of the later stages of Parkinson’s disease – pharmacological approaches now and in the future (2015) (41)
Noradrenaline synthesis from L-DOPA in rodents and its relationship to motor activity (1976) (41)
Nigrostriatal function in vitamin E deficiency: Clinical, experimental, and positron emission tomographic studies (1994) (41)
Differential Toxicity of 6-Hydroxydopamine in SH-SY5Y Human Neuroblastoma Cells and Rat Brain Mitochondria: Protective Role of Catalase and Superoxide Dismutase (2012) (41)
The relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or α-methyl-p-tyrosine pre-treated mice (1976) (41)
Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders (1996) (41)
Dysfunction of rat forebrain astrocytes in culture alters cytokine and neurotrophic factor release (2000) (40)
Adenosine receptors and Parkinson's disease (1999) (40)
Selegiline in narcolepsy. (1986) (40)
Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson's disease. (2001) (40)
Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and l-DOPA treatment (1996) (40)
What process causes nigral cell death in Parkinson's disease? (1992) (40)
Mitochondrial respiratory enzyme function and superoxide dismutase activity following brain glutathione depletion in the rat. (1996) (40)
Iron in the Parkinsonian substantia nigra. (1997) (40)
Levels of MET-enkephalin, LEU-enkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine treatment (1988) (40)
Entacapone enhances levodopa‐induced reversal of motor disability in MPTP‐treated common marmosets (1997) (39)
The dopamine neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmoset (1986) (39)
MPTP treatment of common marmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome (2006) (39)
Do enkephalins in basal ganglia mediate a physiological motor rest mechanism? (1986) (39)
SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors. (1985) (39)
Should there be less emphasis on levodopa‐induced dyskinesia in Parkinson's disease? (2019) (39)
Selective localisation of P450 enzymes and NADPH-P450 oxidoreductase in rat basal ganglia using anti-peptide antisera (1996) (38)
The isomers of thioctic acid alter C-deoxyglucose incorporation in rat basal ganglia. (1996) (38)
Stereoselective actions of substituted benzamide drugs on cerebral dopamine mechanisms (1980) (37)
The RGD‐containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigra (2010) (37)
Altered Motor Function and Graft Survival Produced by Basic Fibroblast Growth Factor in Rats with 6-OHDA Lesions and Fetal Ventral Mesencephalic Grafts Are Associated with Glial Proliferation (1996) (37)
Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson's disease. (2013) (37)
The effect of carbidopa on plasma and muscle levels of L‐dopa, dopamine, and their metabolites following L‐dopa administration to rats (1988) (36)
An appraisal of the antiparkinsonian activity of piribedil in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmosets (1996) (36)
L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates (2007) (36)
Monoamine oxidase activity and distribution in marmoset brain: implications for MPTP toxicity (1988) (36)
6‐Hydroxydopamine increases the hydroxylation and nitration of phenylalanine in vivo: implication of peroxynitrite formation (2001) (36)
Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset (1995) (35)
Role of noradrenaline in levodopa reversal of reserpine akinesia. (1974) (35)
5-Hydroxytryptophan-induced myoclonus in guinea pigs A physiological and pharmacological investigation (1978) (35)
The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety (1985) (35)
Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets (2008) (35)
Transdermal Administration of Piribedil Reverses MPTP-induced Motor Deficits in the Common Marmoset (2000) (34)
Adenosine A2A receptor mRNA expression in Parkinson's disease (2000) (34)
Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat (2005) (34)
Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts (1999) (34)
Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response (2008) (33)
Adenosine A₂A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets. (2014) (33)
Pharmacological analysis of the myoclonus induced by 5-hydroxytryptophan in the guinea pig suggests the presence of multiple 5-hydroxytryptamine receptors in the brain (1981) (33)
Multiple Dopamine Receptors in Brain and the Pharmacological Action of Substituted Benzamide Drugs (1984) (33)
Potent lipophilic substituted benzamide drugs are not selective D‐1 dopamine receptor antagonists in the rat (1983) (32)
Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson’s disease (2012) (32)
Dopamine D3 receptors are not involved in the induction of c-fos mRNA by neuroleptic drugs: comparison of the dopamine D3 receptor antagonist GR103691 with typical and atypical neuroleptics. (1996) (32)
Lack of Change in Basal Ganglia Neuropeptide Content Following Subacute 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Treatment of the Common Marmoset (1986) (31)
The involvement of noradrenaline in motor activity as shown by rotational behaviour after unilateral lesions of the locus coeruleus. (1976) (31)
Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems (2008) (31)
Effect and mechanism of acupuncture on Alzheimer's disease. (2013) (31)
Differential labelling of dopamine receptors in rat brain in vivo: comparison of [3H]piribedil, [3H]S 3608 and [3H]N,n-propylnorapomorphine. (1983) (31)
The effect of bromocriptine on locomotor activity and cerebral catecholamines in rodents (1977) (30)
in vitro characterisation of dopamine receptors in the superior colliculus of the rat (1987) (30)
Characterization of neurotensin-like immunoreactivity in human basal ganglia: Increased neurotensin levels in substantia nigra in Parkinson's disease (1995) (30)
FUNCTIONAL CHANGES IN CEREBRAL 5‐HYDROXYTRYPTAMINE METABOLISM IN THE MOUSE INDUCED BY ANTICONVULSANT DRUGS (1978) (30)
The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease (1995) (30)
Osteopontin (Eta-1) is present in the rat basal ganglia. (2004) (30)
An in vivo pharmacological evaluation of pardoprunox (SLV308) — A novel combined dopamine D2/D3 receptor partial agonist and 5-HT1A receptor agonist with efficacy in experimental models of Parkinson's disease (2010) (30)
Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease (2021) (30)
Rotational behaviour produced in rats by unilateral electrolytic lesions of the ascending noradrenergic bundles (1977) (30)
Specific [3H]Piflutixol Binding to CHAPS‐Solubilised Rat Striatal Preparations Involves Dopamine D‐2 but Not D‐1 Binding Sites (1986) (29)
Nitric oxide synthase inhibition and MPTP‐induced toxicity in the common marmoset (1997) (29)
Disorders of movement : clinical, pharmacological and physiological aspects (1989) (29)
The effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal and limbic catecholamine neurones in white and black mice antagonism by monoamine oxidase inhibitors Antagonism by monoamine oxidase inhibitors (1986) (29)
Repeated administration of sulpiride for three weeks produces behavioural and biochemical evidence for cerebral dopamine receptor supersensitivity. (1982) (29)
Localization of neurotensin receptors in the forebrain of the common marmoset and the effects of treatment with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (1987) (29)
Involvement of intrinsic cholinergic and GABAergic innervation in the effect of NMDA on striatal dopamine efflux and metabolism as assessed by microdialysis studies in freely moving rats (2001) (29)
Beginning‐of‐dose and rebound worsening in MPTP‐treated common marmosets treated with levodopa (2002) (29)
Behavioural effects in rats of unilateral and bilateral injections of opiate receptor agonists into the globus pallidus (1985) (29)
Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or l-DOPA in MPTP-treated common marmosets (2010) (29)
Dopamine Uptake Inhibitor-Induced Rotation in 6-Hydroxydopamine-Lesioned Rats Involves Both D1 and D2 Receptors but Is Modulated through 5-Hydroxytryptamine and Noradrenaline Receptors (2005) (28)
Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to normal common marmosets (2005) (28)
Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates. (2002) (28)
Debrisoquine hydroxylation in Parkinson's disease (1992) (28)
Oxidative stress and Parkinson's disease. (2007) (28)
BEHAVIOURAL CHANGES INDUCED BY N,N‐DIMETHYLTRYPTAMINE IN RODENTS (1980) (28)
MPTP-induced parkinsonism in the common marmoset: behavioral and biochemical effects. (1987) (28)
Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study (1994) (28)
Leukocyte glutamate dehydrogenase activity in patients with degenerative neurological disorders. (1988) (28)
Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-Methyl-D-aspartate receptor antagonists—II. Pharmacological characterization in vivo (1996) (28)
Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset. (1995) (28)
Differential alteration of striatal D-1 and D-2 receptors induced by the long-term administration of haloperidol, sulpiride or clozapine to rats. (1985) (28)
The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets. (2015) (27)
The effect of nitric oxide synthase inhibition on quinolinic acid toxicity in the rat striatum (1995) (27)
The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets (2010) (27)
The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets. (2015) (27)
Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss (2007) (27)
Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of parkinson's disease — the differential effects of D1 dopamine antagonists in the primate (1995) (27)
Acute effects of D-1 and D-2 dopamine receptor agonist and antagonist drugs on basal ganglia [Met5]- and [Leu5]-enkephalin and neurotensin content in the rat. (1991) (27)
5-Hydroxytryptamine (5-HT)-dependent myoclonus in guinea pigs is induced through brainstem 5-HT-1 receptors (1984) (27)
Effect of chronic treatment with typical and atypical neuroleptics on the expression of dopamine D2 and D3 receptors in rat brain (1996) (27)
Pilocarpine-induced purposeless chewing behaviour in rats is dependent on intact central stores of 5-HT. (1987) (27)
Differentiation of dopamine agonists using drug-induced rotation in rats with unilateral or bilateral 6-hydroxydopamine destruction of ascending dopamine pathways. (1983) (26)
The mode of action of sulpiride as an atypical antidepressant agent. (1982) (26)
Antiparkinsonian activity of adenosine A2A antagonists in experimental models. (1999) (26)
Hypophysectomy does not prevent development of striatal dopamine receptor supersensitivity induced by repeated neuroleptic treatment. (1981) (26)
Is the dopamine hypothesis of tardive dyskinesia completely wrong? (1986) (26)
Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat (2004) (26)
Alterations in motor behaviour produced by the isomers of 3-PPP in the MPTP-treated marmoset. (1986) (26)
L-dopa's action in parkinson's disease (1981) (26)
L‐Arginine produces NO‐independent increases in dopamine efflux in rat striatum (1998) (25)
Current development of acupuncture research in Parkinson's disease. (2013) (25)
Persistent increase in striatal dopamine stimulated adenylate cyclase activity persists for more than 6 months but disappears after 1 year following withdrawal from 18 months cis-flupenthixol intake. (1983) (25)
[3H]SCH 23390 identifies D‐1 binding sites in rat striatum and other brain areas (1986) (25)
Cation specificity of 3H-sulpiride binding involves alteration in the number of striatal binding sites. (1983) (25)
BRAIN MUSCARINIC RECEPTORS IN ALZHEIMER'S AND PARKINSON'S DISEASES (1989) (25)
Brain muscarinic cholinergic receptors in Huntington's disease (1992) (24)
Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets (2010) (24)
The administration of entacapone prevents l-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates (2007) (24)
Differential alterations in striatal acetylcholine function in rats during 12 months' continuous administration of haloperidol, sulpiride, or clozapine. (1986) (24)
Antiparkinsonian activity of (+)‐PHNO in the MPTP‐treated common marmoset (1987) (24)
Plasma DOPA levels and growth hormone response to levodopa in parkinsomism. (1977) (24)
Alterations in [Met5]- and [Leu5]enkephalin and neurotensin content in basal ganglia induced by the long-term administration of dopamine agonist and antagonist drugs to rats. (1986) (24)
Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. (1987) (23)
Manipulation of Cerebral Monoamines in the Treatment of Human Epilepsy: A Pilot Study (1978) (23)
The effects of dopamine and dopamine agonists on the release of 3H-GABA and 3H-5HT from rat nigral slices. (1985) (23)
An immunohistochemical and stereological analysis of PSI‐induced nigral neuronal degeneration in the rat (2009) (23)
Receptor changes during chronic dopaminergic stimulation. (1988) (23)
The pharmacological characterisation of pilocarpine-induced purposeless chewing behaviour in the rat (2006) (23)
P450 and heme oxygenase enzymes in the basal ganglia and their roles in Parkinson's disease. (1999) (23)
The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (1989) (23)
MPP+ can disrupt the nigrostriatal dopamine system by acting in the terminal area (1986) (23)
Tryptamine-induced myoclonus in guinea-pigs pretreated with a monoamine oxidase inhibitor indicates pre- and post-synaptic actions of tryptamine upon central indoleamine systems (1982) (23)
Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease—Viewpoint (2020) (22)
Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets (1999) (22)
Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6‐OHDA‐lesioned rats (2011) (22)
Neuronal nitric oxide synthase inhibition reduces MPP+-evoked hydroxyl radical formation but not dopamine efflux in rat striatum (1999) (22)
Can therapeutic strategies prevent and manage dyskinesia in Parkinson’s disease? An update (2019) (22)
Metabolite involvement in bromocriptine‐induced circling behaviour in rodents (1980) (22)
The effect of diphenylhydantoin on central catecholamine containing neuronal systems (1977) (22)
Inhibition of neuronal nitric oxide synthase increases dopamine efflux from rat striatum (2003) (22)
Chronic high dose l-dopa treatment does not alter the levels of dopamine D-1, D-2 or D-3 receptor in the striatum of normal monkeys: an autoradiographic study (2001) (22)
Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets (2005) (22)
Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP (1991) (21)
Comparison of HPLC and Enzymatic Recycling Assays for the Measurement of Oxidized Glutathione in Rat Brain (1997) (21)
Expression and distribution of CYP2C enzymes in rat basal ganglia (2000) (21)
Behavioural and biochemical alterations in the function of dopamine receptors following repeated administration of l-DOPA to rats (1984) (21)
An experimental model of tardive dyskinesias. (1978) (21)
Neurobiology of Amino Acids, Peptides and Trophic Factors (1989) (21)
Folate and monoamine metabolism in epilepsy (1975) (21)
Behavioural and morphological changes following treatment with GM-1 ganglioside of rats with an electrolytic lesion of the substantia nigra (1989) (21)
Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease. (2010) (21)
Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats (2004) (21)
Contraversive circling behaviour produced by unilateral electrolytic lesions of the ventral noradrenergic bundle mimicking the changes seen with unilateral electrolytic lesions of the locus coeruleus (1976) (21)
Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP‐treated common marmosets (2010) (20)
Myoclonus in guniea pigs is induced by indole-containing but not piperazine-containing 5HT agonists. (1982) (20)
GABAergic modulation of striatal peptide expression in rats and the alterations induced by dopamine antagonist treatment (1994) (20)
Nonmotor Symptoms in Experimental Models of Parkinson's Disease. (2017) (20)
The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP‐treated primates (2004) (20)
The significance of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. (1987) (20)
Drugs acting at D-1 and D-2 dopamine receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulation (2005) (20)
Serotonergic sprouting in the neostriatum after intrastriatal transplantation of fetal ventral mesencephalon (1991) (20)
Commonly used L-amino acid decarboxylase inhibitors block monoamine oxidase activity in the rat (2003) (20)
Oxidative Stress in Neurological Disease (1999) (20)
Intravenous boluses and continuous infusions of L‐DOPA methyl ester in fluctuating patients with Parkinson's disease (1992) (19)
A comparison of motor behaviours in groups of rats distinguished by their climbing response to apomorphine (1986) (19)
Alterations in different populations of striatal dopamine receptors produced by 18 months continuous administration of cis- or trans-flupenthixol to rats (1984) (19)
l‐Dopa esters as potential prodrugs: effect on brain concentration of dopamine metabolites in reserpinized mice ‡ (1987) (19)
3-Nitrotyrosine-dependent dopaminergic neurotoxicity following direct nigral administration of a peroxynitrite but not a nitric oxide donor (2006) (19)
Chronic neuroleptic treatment specifically alters the number of dopamine receptors in rat brain. (1981) (19)
Reduction in cortical 5-HT3 binding sites following a unilateral 6-hydroxydopamine lesion of the medial forebrain bundle in rats (1993) (19)
Dopamine receptor subtypes : from basic science to clinical application (1998) (19)
The role of nigral projections to the thalamus in drug-induced circling behaviour in the rat. (1981) (19)
Letter: Amines, anticonvulsants, and epilepsy. (1975) (19)
A yeast two‐hybrid screen reveals that osteopontin associates with MAP1A and MAP1B in addition to other proteins linked to microtubule stability, apoptosis and protein degradation in the human brain (2012) (19)
Acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the adrenal glands as well as the brain in the marmoset (1985) (18)
Assessment of the muscarinic receptor subtype involved in the mediation of pilocarpine-induced purposeless chewing behaviour (2004) (18)
Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-Dopa. (2017) (18)
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience (2021) (18)
Dissociation of the striatal D-2 dopamine receptor from adenylyl cyclase following 6-hydroxydopamine-induced denervation. (1992) (18)
Parallel alterations in Met-enkephalin and substance P levels in medial globus pallidus in Parkinson's disease patients (1993) (18)
The actions of a D-1 agonist in MPTP treated primates show dependence on both D-1 and D-2 receptor function and tolerance on repeated administration (2002) (18)
Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future (2021) (18)
Peripheral Pharmacokinetic Handling and Metabolism of L‐Dopa in the Rat: The Effect of Route of Administration and Carbidopa Pretreatment (1991) (18)
Expression of integrin and CD44 receptors recognising osteopontin in the normal and LPS‐lesioned rat substantia nigra (2013) (18)
L-DOPA esters as potential prodrugs. I: Physicochemical properties (1985) (17)
Specific receptors for substituted benzamide drugs in brain. (1982) (17)
Alterations in expression of dopamine receptors and neuropeptides in the striatum of GTP cyclohydrolase-deficient mice (2004) (17)
Pharmacological evidence for cerebral dopamine receptor blockade by metoclopramide in rodents (2004) (17)
Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson’s disease (2020) (17)
The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L‐DOPA and dopamine agonists in MPTP‐treated primates (2000) (17)
Parkinson's disease: pathological mechanisms and actions of piribedil (1992) (17)
Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity (2005) (17)
Changes in cerebral dopamine function induced by a year's administration of trifluoperazine or thioridazine and their subsequent withdrawal. (1980) (17)
Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates (2007) (16)
Drug-induced circling after unilateral 6-hydroxydopamine lesions of the nigro-striatal pathway is mediated via the midbrain periaqueductal grey and adjacent reticular formation (angular complex). (1981) (16)
Noradrenaline-sensitive adenylate cyclase in slices of mouse limbic forebrain: characterisation and effect of dopaminergic agonists. (1977) (16)
The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset. (2010) (16)
Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. (1992) (15)
Glutamatergic regulation of striatal peptide gene expression in rats (1995) (15)
Alterations in brain 5HT and tryptamine content during indoleamine-induced myoclonus in guinea pigs. (1983) (15)
New approaches to therapy. (2011) (15)
(+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE IN PARKINSON'S DISEASE (1986) (15)
Adaptive changes in brain dopamine function as a result of neuroleptic treatment. (1988) (15)
Effect of 7‐nitro indazole on quinolinic acid‐induced striatal toxicity in the rat (1995) (15)
The dopamine D2 receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with l-dopa (2009) (15)
Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease? (2020) (15)
Elevation of circulating prolactin concentrations may not cause striatal dopamine receptor supersensitivity. (1983) (15)
Role of inducible nitric oxide synthase in N-methyl-d-aspartic acid-induced strio-nigral degeneration (2004) (15)
Cortical nicotinic receptors in Alzheimer's disease and Parkinson's disease. (1991) (14)
Administration of MPTP to the common marmoset does not alter cortical cholinergic function (1986) (14)
Motor function, graft survival and gliosis in rats with 6-OHDA lesions and foetal ventral mesencephalic grafts chronically treated with L-DOPA and carbidopa (2005) (14)
The effect of Banisteriopsis caapi (B. caapi) on the motor deficits in the MPTP‐treated common marmoset model of Parkinson's disease (2018) (14)
Properties of rat striatal D‐2 dopamine receptors solubilized with the zwitterionic detergent CHAPS (1985) (14)
Circling behavior following unilateral kainic acid injections into rat striatum. (1981) (14)
Acute and repeated administration of sulpiride alters Met- and Leu-enkephalin content of rat brain (1986) (13)
During one year's neuroleptic treatment in rats striatal dopamine receptor blockade decreases but serum prolactin levels remain elevated. (1981) (13)
Pharmacological characterization of binding sites identified in rat brain following in vivo administration of [3H]‐spiperone. (1987) (13)
Improving the Delivery of Levodopa in Parkinson’s Disease: A Review of Approved and Emerging Therapies (2020) (13)
Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone (2021) (13)
Mitochondria, monoamine oxidase B and Parkinson’s disease (2012) (13)
Comparison of the acute actions of amine-depleting drugs and dopamine receptor antagonists on dopamine function in the brain in rats (1987) (13)
A comparison of the effects of acute and one year's continuous neuroleptic treatment on the release of [3H]glutamate and [3H]acetylcholine from rat striatal slices (1984) (13)
Lesions of the globus pallidus, entopeduncular nucleus and substantia nigra alter dopamine mediated circling behaviour (2004) (13)
Modafinil prevents the MPTP-induced increase in GABAA receptor binding in the internal globus pallidus of MPTP-treated common marmosets (2004) (12)
Unilateral pallidotomy in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmosets exhibiting levodopa‐induced dyskinesia (2005) (12)
Serum Uric Acid Levels and Non-Motor Symptoms in Parkinson's Disease. (2020) (12)
Treatment of posthypoxic action myoclonus: implications for the pathophysiology of the disorder. (1986) (12)
Urea-induced stimulus-sensitive myoclonus in the rat. (1986) (12)
Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson’s disease (2017) (12)
Pathology of MPTP in the marmoset. (1987) (12)
Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture (2012) (12)
The effect of long-term treatment with amine-depleting drugs or chlorpromazine on α-adrenoreceptors and 5-HT2 receptors in the brain of the rat (1988) (12)
TREATMENT OF NARCOLEPSY WITH L-TYROSINE: DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (1989) (12)
The effect of nNOS inhibitors on toxin-induced cell death in dopaminergic cell lines depends on the extent of enzyme expression (2011) (12)
Genetic susceptibility and the occurrence of Parkinson's disease. (1999) (12)
Age-related decreases in the concentration of Met-and Leu-enkephalin and neurotensin in the basal ganglia of rats (1987) (11)
Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists--II. Pharmacological characterization in vivo. (1996) (11)
An autoradiographic study of the differential effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on striatal and extrastriatal D-1 and D-2 dopamine receptors in the rat (1994) (11)
Increased [Met]enkephalin and decreased substance p in spinal cord following thermal injury to one limb (1990) (11)
Basal ganglia outflow pathways and circling behaviour in the rat (2005) (11)
Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain (2005) (11)
The interaction of clonidine with dopamine-dependent behaviour in rodents (1977) (11)
Turnover of specific [3H]spiperone and [3H]N,n-propylnorapomorphine binding sites in rat striatum following phenoxybenzamine administration. (1983) (11)
Loss of locus coeruleus noradrenergic neurons alters the inflammatory response to LPS in substantia nigra but does not affect nigral cell loss (2014) (11)
Long-term adaptive changes in striatal dopamine function in response to chronic neuroleptic intake in rats. (1983) (11)
Contractile dysfunction and nitrergic dysregulation in small intestine of a primate model of Parkinson’s disease (2019) (11)
Acute and subchronic effects of dopamine agonists on neuropeptide gene expression in the rat striatum (1995) (11)
Presymptomatic detection of Parkinson's disease. (1993) (11)
Up-regulation of secretoneurin immunoreactivity and secretogranin II mRNA in rat striatum following 6-hydroxydopamine lesioning and chronic L-DOPA treatment (2001) (11)
Comparison of changes in locomotor activity with striatal homovanillic acid and 3,4‐dihydroxyphenylacetic acid concentrations following the bilateral intranigral injection of dopamine agonist drugs in rats (1987) (11)
Oxidative stress in Parkinson's disease. Discussion (2003) (11)
The Neurobiology of Dopamine (1980) (11)
Halothane Anesthesia Affects NMDA-Stimulated Cholinergic and GABAergic Modulation of Striatal Dopamine Efflux and Metabolism in the Rat In Vivo (2004) (11)
The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatment (1985) (11)
Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6‐hydroxydopamine lesioned rat without sensitizing motor behaviours (2005) (11)
Alterations in cerebral glutamic acid decarboxylase and3H-flunitrazepam binding during continuous treatment of rats for up to 1 year with haloperidol, sulpiride or clozapine (2005) (11)
Parkinson's disease is rarely a primary cause of death (1996) (11)
Isocratic reverse-phase HPLC separation and RIA used in the analysis of neuropeptides in brain tissue (1991) (11)
Can adenosine A2A receptor antagonists modify motor behavior and dyskinesia in experimental models of Parkinson's disease? (2020) (10)
Gamma-aminobutyric acid and basal ganglia outflow pathways. (1984) (10)
Neurochemical basis of parkinsonian tremor (1984) (10)
Inhibition of i-NOS but not n-NOS protects rat primary cell cultures against MPP+-induced neuronal toxicity (2015) (10)
Increased neurotrophic factor levels in ventral mesencephalic cultures do not explain the protective effect of osteopontin and the synthetic 15-mer RGD domain against MPP+ toxicity (2015) (10)
Altered detrusor contractility in MPTP-treated common marmosets with bladder hyperreflexia (2017) (10)
The central aromatic amino acid DOPA decarboxylase inhibitor, NSD‐1015, does not inhibit l‐DOPA‐induced circling in unilateral 6‐OHDA‐lesioned‐rats (2001) (10)
Animal models of neuroleptic-induced acute dystonia. (1988) (10)
Increased striatal acetylcholine after 14 months cis-flupenthixol treatment in rats suggests functional supersensitivity of dopamine receptors. (1982) (10)
Myoclonus in the rat induced by p,p'-DDT and the role of altered monoamine function (1985) (10)
Antagonism by propranolol of central dopamine receptor stimulation is not related to β‐adrenergic blockade (1979) (10)
Dopamine mediated circling behaviour is modulated by lesions of the ventromedial nucleus of the thalamus [proceedings]. (1979) (10)
Proceedings: Behavioural and biochemical evidence for cerebral dopamine receptor blockade by metoclopramide in rodents. (1975) (10)
Stress and cortisol in Parkinson's disease. (2020) (10)
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination]. (2005) (10)
Repeated administration of escalating high doses of dexfenfluramine does not produce morphological evidence for neurotoxicity in the cortex of rats. (1996) (9)
Effects of somatostatin on dopamine sensitive adenylate cyclase activity in the caudate-putamen of the rat (2004) (9)
Clinical overview and phenomenology of movement disorders (2021) (9)
Striatal leucine‐rich repeat kinase 2 mRNA is increased in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned common marmosets (Callithrix jacchus) with l‐3, 4‐dihydroxyphenylalanine methyl ester‐induced dyskinesia (2007) (9)
Design, synthesis and biological evaluation of peptide derivatives of L-dopa as anti-parkinsonian agents. (2013) (9)
Apomorphine infusion in advanced Parkinson disease (2018) (9)
Correlation of [3H]5-hydroxytryptamine (5HT) binding to brain stem preparations and the production and prevention of myoclonus in guinea pig by 5HT agonists and antagonists. (1984) (9)
6-Hydroxydopamine lesioning differentially affects α-synuclein mRNA expression in the nucleus accumbens, striatum and substantia nigra of adult rats (2002) (9)
A major metabolite of bupropion reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets (2011) (9)
Adenosine A2A-receptor antagonists: beyond dopaminergic therapies for Parkinson's disease (2004) (8)
Endogenous dopaminergic tone and dopamine agonist action (2000) (8)
The Role of Glutamate in the Healthy Brain and in the Pathophysiology of Parkinson’s Disease (2019) (8)
Glial cells and abnormal protein handling in the pathogenesis of Parkinson's disease. (2001) (8)
Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats (2013) (8)
Differential ability of selective and non-selective dopamine agonists to induce climbing in the rat indicates the involvement of both D-1 and D-2 receptors in this behaviour (2005) (8)
Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion (2005) (8)
Plasma propranolol in essential tremor (1982) (8)
Charles David Marsden. 15 April 1938 — 29 September 1998 (2012) (8)
The future of parkinson’s treatment – Personalised and precision medicine (2017) (8)
New Symptomatic Treatments for the Management of Motor and Nonmotor Symptoms of Parkinson's Disease. (2017) (8)
A comparison of striatal and mesolimbic dopamine function in the rat during 6-month trifluoperazine administration (2004) (8)
The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats. (2014) (8)
L-DOPA esters as potential prodrugs. II: Chemical and enzymatic hydrolysis (1985) (7)
OBSERVATIONS ON CHLORALOSE‐INDUCED MYOCLONUS IN GUINEA‐PIGS (1980) (7)
Electromyographical differentiation of the components of perioral movements induced by SKF 38393 and physostigmine in the rat (2005) (7)
Chronic Administration Does Not Alter the Pharmacokinetic Profile of l‐Dopa in the Rat (1993) (7)
5-HT-mediated myoclonus in the guinea pig as a model of brainstem 5-HT and tryptamine receptor action. (1986) (7)
Behavioural changes induced by N,N-dimethyltryptamine in rodents [proceedings]. (1978) (7)
Oxyferriscorbone elevates the total iron content of blood but not brain (1989) (7)
Hypophysectomy does not prevent increased cerebral dopamine turnover following sulpiride administration (1983) (7)
Changes in cerebral dopamine metabolism and receptors during one-year neuroleptic administration and subsequent withdrawal: relevance to brain biochemistry in schizophrenia. (1980) (7)
1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-methyl-MPTP) is less neurotoxic than MPTP in the common marmoset. (1990) (7)
Cholinergic manipulation of motor disability and l-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets (2014) (7)
The effects of dose and route of administration of PSI on behavioural and biochemical indices of neuronal degeneration in the rat brain (2010) (7)
Dopamine receptor binding sites in the rat superior colliculus (1984) (7)
Modification of the L-DOPA reversal of reserpine akinesia by inhibitors of dopamine-beta-hydroxylase. (1976) (7)
Oral r‐(‐)‐11‐o‐valeryl‐n‐n‐propylnoraporphine reverses motor deficits in mptp‐treated marmosets (2016) (7)
Dopamine agonists in Parkinson’s disease – focus on non‐motor symptoms (2008) (7)
The influence of piribedil (ET495) on components of locomotor activity. (1975) (7)
Possible Neuronal Mechanisms Involved in the Production of the Disinhibitory Action of Sulpiride (1981) (7)
Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. (1987) (7)
Atropine manipulation of elevated cerebral dopamine turnover caused by haloperidol or substituted benzamide drugs (1978) (7)
Acute reserpine treatment induces down regulation of D-1 dopamine receptor associated adenylyl cyclase activity in rat striatum. (1992) (6)
Interference by alphamethylparatyrosine with three procedures for assay of cerebral catecholamines (1975) (6)
Physiological and Behavioural Effects of Food Constituents (1985) (6)
The treatment of levodopa‐induced dyskinesias: Surfing the serotoninergic wave (2018) (6)
Interpretation of changes in apomorphine-induced stereotyped behaviour in rats receiving continuous administration of trifluoperazine for 15 months (1984) (6)
Actions of Adenosine Antagonists in Primate Model of Parkinson's Disease (2000) (6)
Expression of catechol-O-methyltransferase in the brain and periphery of normal and MPTP-treated common marmosets (2009) (6)
Behavioural effects mediated by unilateral nigral dopamine receptor stimulation in the rat (2004) (6)
[125I] Spiperone is not a useful ligand for studying the CHAPS solubilized dopamine D‐2 receptor from rat striatum (1986) (6)
The Story of Istradefylline—The First Approved A2A Antagonist for the Treatment of Parkinson’s Disease (2015) (6)
Pramipexole protects against apoptotic cell death by non‐dopaminergic mechanisms (2005) (6)
Neuroleptic-induced tardive dyskinesia. (1987) (6)
Neurobiology: Molecular Biological Approaches to Understanding Neuronal Function and Development (1986) (6)
Two hundred years since James Parkinson's essay on the shaking palsy—Have we made progress? Insights from the James Parkinson's 200 years course held in London, March 2017 (2017) (6)
Effect of chronic treatment with typical and atypical neuroleptics on the expression of dopamine D 2 and D 3 receptors in rat brain (6)
A redox reaction between MPP+ and MPDP+ to produce superoxide radicals does not impair mitochondrial function. (1991) (6)
DOSE-DEPENDENT LOCOMOTOR EFFECTS OF BROMOCRIPTINE IN ANIMALS AND MAN — ARE SOME OF ITS ACTIONS DUE TO METABOLITES? (1979) (5)
Amphetamines, growth hormone and narcolepsy. (1977) (5)
Relationship between plasma propranolol levels and the clinical suppression of essential tremor [proceedings]. (1979) (5)
Proceedings: The role of dopamine in rotational behaviour produced by unilateral lesions of the locus coeruleus. (1975) (5)
3‐Methoxy‐4‐hydroxyphenylglycol sulphate (MOPEG‐SO4) as an index of cerebral noradrenaline turnover following depletion of transmitter stores in the rat (1978) (5)
DIFFERENTIAL EFFECTS OF ADMINISTRATION OF HALOPERIDOL, SULPIRIDE OR CLOZAPINE FOR 12 MONTHS ON RAT STRIATAL FUNCTION (1984) (5)
Definition of the In‐vivo Accumulation of [3H]spiperone in Brain using Haloperidol and Sulpiride to Determine Functional Dopamine Receptor Occupation (1988) (5)
The influence of aromatic substituents on the binding of substituted benzamides to dopamine D‐2 receptors: congruent QSAR and MEP analyses (1987) (5)
Richardson et al. reply (1998) (5)
GABA mediated circling from substantia nigra (1980) (5)
The effect of L-dopa and carbidopa on behavioural recovery produced by ventral mesencephalic grafts in rats. (1990) (5)
Nitric oxide and basal ganglia degeneration. (1999) (5)
Proceedings: Is metoclopramide a directly acting dopamine receptor antagonist? (1976) (5)
The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson’s Disease (2022) (5)
The MPTP-Treated Primate, with Specific Reference to the Use of the Common Marmoset ( Callithrix jacchus ) (2011) (5)
The interaction of substituted benzamides with brain benzodiazepine binding sites in vitro (1988) (5)
Alterations in cerebral dopamine function caused by administration ofcis- ortrans-flupenthixol for up to 18 months (1983) (5)
Chapter 5 – Antiparkinsonian and antidyskinetic drugs (1982) (5)
Proteomic Analysis of Striatum from MPTP-Treated Marmosets (Callithrix jacchus) with l-DOPA-Induced Dyskinesia of Differing Severity (2014) (4)
Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs (2005) (4)
Dopamine-mediated circling behaviour does not involve the nigro-tectal pathway (1979) (4)
The effect of chronic administration and withdrawal of amphetamine on cerebral dopamine receptor sensitivity (1978) (4)
Proceedings: Clonazepam-induced changes in 5-hydroxytryptamine (5-HT) metabolism in aminals and man. (1975) (4)
Effects of continuous administration for 12 months of amine-depleting drugs and chlorpromazine on striatal dopamine function in the rat (1987) (4)
Altered serotoninergic activity in mouse brain induced by clonazepam [proceedings]. (1978) (4)
Chronic administration does not alter the accumulation of L‐dopa into muscle (2004) (4)
p,p'-DDT-induced myoclonus in the rat and its application as an animal model of 5-HT-sensitive action myoclonus. (1986) (4)
Adrenoreceptor antagonists in essential tremor (4)
‘Dopamine agonist Phobia’ in Parkinson’s disease: when does it matter? Implications for non-motor symptoms and personalized medicine (2020) (4)
Chronic trifluoperazine treatment does not induce lipid peroxidation in the rat cortex (1987) (3)
Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398 (2008) (3)
Critical role of midbrain reticular formation in the expression of dopamine-mediated circling behaviour. (1981) (3)
Regional changes in brain dopamine receptor function during six months trifluoperazine administration to rats [proceedings]. (1980) (3)
D1 or D2 receptor-induced purposeless chewing in rats is differentially modulated by cholinergic drugs. (1989) (3)
Multivariate statistical analysis of L-dopa esters as potential anti-parkinsonian prodrugs. (1987) (3)
Behavioural and biochemical effects of chronic reduction of cerebral noradrenaline receptor stimulation (1977) (3)
Supersensitivity of cerebral dopamine receptors during on-going chronic (six months) administration of trifluoperazine to rats [proceedings]. (1978) (3)
Hyperprolactinaemia does not alter specific striatal 3H-spiperone binding in the rat. (1986) (3)
BASAL GANGLIA NEUROPEPTIDE ALTERATIONS IN PARKINSON??S DISEASE AND CONTROLS BEARING LEWY BODIES (1992) (3)
The absence of sodium ions does not explain the failure of sulpiride to inhibit, in vitro, rat striatal dopamine‐sensitive adenylate cyclase (1981) (3)
Chapter 14 – The Relevance of Adenosine A2A Antagonists to the Treatment of Parkinson's Disease: Concluding Remarks (2000) (3)
Chapter 24 – Restless Legs Syndrome and Peripheral Movement Disorders (2007) (3)
Antiparkinsonian activity of L‐propyl‐L‐leucyl‐glycinamide or melanocyte‐inhibiting factor in MPTP‐treated common marmosets (2007) (3)
Lack of effect of intranigral administration of a dopamine analogue, (±)-3-(3-hydroxyphenyl)-N,n-propylpiperidine [(±)-3-PPP], on nigrostriatal dopamine neurones (1985) (3)
Pramipexole protects against rotenone toxicity: Mechanisms and implications (2002) (3)
Effects of discontinuous drug administration on the development of dopamine receptor supersensitivity during chronic trifluoperazine or cis-flupenthixol administration to rats (2004) (3)
Effect of chronic trifluoperazine administration and subsequent withdrawal on the production and persistence of perioral behaviours in two rat strains (2005) (3)
Functional increase in striatal dopaminergic activity following continuous long-term treatment with trifluoperazine (1984) (3)
Erratum: Levodopa in the treatment of Parkinson's disease: Current controversies (Movement Disorders) (2004)) (2005) (3)
The irritant properties of dopamine‐β‐hydroxylase inhibitors in relation to their effects on L‐dopa‐induced locomotor activity (1976) (3)
Levodopa-induced dyskinesias - Foreword (2000) (2)
Biomarkers for Alzheimer's disease: a controversial topic (2015) (2)
Transplantation of embryonic mesencephalic and medullary raphe neurons to the neostriatum of rats with unilateral 6-hydroxydopamine lesions (1992) (2)
Plasticity in dopamine-depleted neonates (1991) (2)
Enhancement of stereotypy induced by nomifensine in rats during continuous chronic haloperidol treatment (1984) (2)
Proceedings: The mechanism of the effect of dopamine-beta-hydroxylase inhibitor FLA-63 on the L-DOPA reversal of reserpine akinesia. (1975) (2)
News on NOS: Neuronal nitric oxide synthase as a drug target (1994) (2)
Anticonvulsant Drugs Produce Different Effects on Plasma Tryptophan Concentrations in Epileptic Patients (1984) (2)
Substituted benzamides as dopamine antagonists (1976) (2)
NEUROLEPTIC DRUGS AND THE DOPAMINE HYPOTHESIS (1979) (2)
Partial reversal of increased preproenkephalin messenger ribonucleic acid (mRNA) and decreased preprotachykinin mRNA by foetal dopamine cells in unilateral 6‐Hydroxydopamine–Lesioned rat striatum parallels functional recovery (1996) (2)
Behavioural effects of allylglycine (2-amino-4-pentenoic acid) and 2-keto-4-pentenoic acid following focal injection into the rat cerebellum and caudate nucleus [proceedings]. (1978) (2)
Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat (2012) (2)
Excitotoxins. (Wenner-Gren International Symposium Series; Vol 39.) (1985) (2)
Dysfunction of the ubiquitin–proteasome system in Parkinson's disease (2003) (2)
Dyskinesia Matters: But Not as Much as It Used to (2020) (2)
A cup of coffee a day keeps dyskinesia away? (2013) (2)
Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex (2013) (2)
Prevention and Treatment of Cerebrovascular Disease (1987) (2)
The effect of low dose carbidopa/levodopa on prolactin and growth hormone concentrations in patients with breast cancer and in benign breast tumours. (1978) (2)
Definition of the In‐vivo Binding of [3H]Spiperone in Rat Brain Using Substituted Benzamide Drugs (1989) (2)
Superior colliculus lesions do not alter dopamine mediated circling behaviour [proceedings]. (1979) (2)
5‐HYDROXYTRYPTAMINE AND MYOCLONUS INDUCED BY 1,2‐DI‐HYDROXYBENZENE (CATECHOL) IN THE GUINEA‐PIG (1979) (2)
Research report Dopamine D 3 :receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment (1996) (2)
Interaction of clonidine with dopamine-dependent behaviours in rodents [proceedings]. (1976) (1)
Affinity of pyridylalkylamines for nicotinic, muscarinic and histaminic recognition sites in brain tissue preparations. (1986) (1)
2.448 Reversal of motor deficits without dyskinesia induction by continuous delivery of ropinirole in MPTP-treated common marmosets (2007) (1)
Neural Grafting in the Mammalian CNS. (Fernstrom Foundation Series.) (1986) (1)
Physiological and Functional Changes in the Colon of MPTP-Treated Common Marmosets (2014) (1)
Dysregulation of epithelial ion transport and neurochemical changes in the colon of a parkinsonian primate (2021) (1)
Proceedings: Biochemical evidence for the involvement of noradrenaline in motor activity produced by L-DOPA in rodents. (1975) (1)
Changes in GABAB1A and GABAB2 receptor gene expression in the basal ganglia and thalamus of rats with a nigrostriatal tract lesion (2000) (1)
Dopamine and somatostatin modulated adenylate cyclase activity in the rat caudate-putamen following unilateral cortical ablation (2004) (1)
Parkinson’s Inside Out (2016) (1)
Neuroreceptors Basic and Clinical Aspects (1982) (1)
Plasma HVA levels following debrisoquine administration do not reflect cerebral dopamine loss in early Parkinson's disease. (1994) (1)
Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease (2023) (1)
The Involvement of the Superior Colliculus and Midbrain Reticular Formation in the Expression of Circling Behaviour (1982) (1)
P2.090 A preliminary pharmacokinetic study comparing L-Dopa and Duodopa in adult rats (2009) (1)
Cortical muscarinic receptors in demented patients with Alzheimer's disease or Parkinson's disease. (1989) (1)
International Review of Neurobiology (1998) (1)
The effect of fenfluramine dosage regimen and reduced food intake on levels of 5-HT in rat brain (2005) (1)
Dopamine Neurone Destruction in Human and Animal Parkinsonism (1986) (1)
Substituted benzamides as dopamine antagonists [proceedings]. (1976) (1)
Norepinephrine. (Frontiers of Clinical Neuroscience Series Vol. 2.) (1985) (1)
Dementia in Parkinson’s Disease and Central Cholinergic Function (1990) (1)
Terguride, a Dopamine Partial Agonist for the Treatment of Parkinson’s Disease (1990) (1)
Parkinsonian Syndrome Caused by 1-Methyl-4-Phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Man and Animals (1987) (1)
Interactions of substituted benzamide drugs with cerebral dopamine pathways [proceedings]. (1977) (1)
ROLE OF DOPAMINE IN ROTATIONAL BEHAVIOR PRODUCED BY UNILATERAL LESIONS OF LOCUS COERULEUS (1975) (1)
Lisuride and Proterguride Reverse MPTP-Induced Parkinsonism in the Common Marmoset (1990) (1)
Reply to: “Parkinson disease‐associated dyskinesia in countries with low access to levodopa‐sparing Regimens“ (2019) (1)
Ecstasy (3,4-Methylenedioxymethamphetamine) inhibits dyskinesia expression and normalises locomotor activity in parkinsonian primates (2002) (1)
SLV 308: plasma levels of effective doses in MPTP‐treated marmosets in comparison with plasma levels and D2 receptor occupancy (PET) in humans (2004) (1)
The binding of [3H]N-(chloroethyl)-norapomorphine to rat striatal membranes. (1984) (1)
Evidence for metabolite involvement in bromocryptine-induced circling behaviour [proceedings]. (1979) (1)
Neuroleptic‐induced acute dystonic reactions may be due to enhanced dopamine release on to supersensitive postsynaptic receptors (1981) (1)
5-Hydroxytryptophan-induced behaviour in guinea-pigs: its relevance to human myoclonus [proceedings]. (1977) (1)
Metal Ions in Neurology and Psychiatry (Neurology and Neurobiology Vol 15). (1987) (0)
Modulation of picrotoxin-induced forepaw myoclonus in the rat by benzodiazepines [proceedings]. (1979) (0)
Osteopontin and tyrosine hydroxylase expression following intranigral injection of lipopolysaccharide (2003) (0)
Fluctuations in response to L-dopa in Parkinson's disease may be explained by changes in striatal dopamine turnover. (1989) (0)
International Review of Neurobiology: Volume 48 (2001) (0)
International review of neurobiology. Vol. 56 (2003) (0)
The novel dopamine D2 receptor partial agonist, SLV-308, reverses motor disability in MPTP-lesioned common marmosets (Callithrix jacchus). (2001) (0)
Drugs and the Nervous System (1987) (0)
Donald B. Calne, Giancarlo Comi, Donatella Grippa, Reinhard Horowski and Marco Trabucchi (eds), Parkinsonism and Aging, Raven Press, New York, 1989, 229 pp., $94.00, ISBN 0 881 67502 4. (1990) (0)
Gerald Malcolm Stern b.1930 d.2018 (2020) (0)
A COMPARISON OF THE EFFECTS OF CHRONIC (SIX MONTH) ADMINISTRATION OF TRIFLUOPERAZINE AND THIORIDAZINE ON STRIATAL DOPAMINE FUNCTION IN RATS (1979) (0)
Receptors and Ligands in Neurological Disorders. Intercellular and Intracellular Communication series Vol 4 (1989) (0)
Effect of the mitochondrial complex I inhibitor MPP+ and the proteasomal inhibitor lactacystin on SH-SY5Y cells (2003) (0)
Hypophysectomy may non-selectively alter pharmacokinetic parameters to enhance the ability of haloperidol to increase striatal dopamine receptor density in the rat. (1986) (0)
A Molecular Biology Approach to Parkinson's Disease (1999) (0)
Treatment of Diseases of Nerve and Muscle (1987) (0)
Characteristics of the Solubilised D-2 Dopamine Receptor from Rat Striatum (1986) (0)
L-DOPA, ropinirole and bromocriptine have a differential effect on srtiatal glutamic acid decarboxylase 65 and 67 mRNA expression in MPTP-treated marmosets (2004) (0)
Continuous dopaminergic stimulation with levodopa plus entacapone (2003) (0)
The effects of pallidotomy on motor function in MPTP-treated, L-DOPA primed common marmosets (2004) (0)
Advances in the pharmacology and treatment of Parkinson's disease (2003) (0)
Effect of cytochrome P4502E1 inhibition on free radical formation and dopamine efflux in the rat substantia nigra (2002) (0)
The spontaneous and neurogenic contractile responses of the isolated bladder smooth muscle are markedly enhanced in MPTP treated common marmoset (Callithrix jacchus) (2013) (0)
Reply (1993) (0)
CHOLINERGIC MARKERS IN ALZHEIMERS-DISEASE AND PARKINSONS-DISEASE (1990) (0)
Central properties of alpha-allophanyl-alpha-allyl-gamma-valerolactone (valofan) [proceedings]. (1979) (0)
Treatment of Movement Disorders (1987) (0)
Substituted Benzamide Drugs as Selective Agents for Distinguishing Cerebral Dopamine Receptor Sub-types (1983) (0)
Subject Index Vol. 27, Suppl 1, 1987 (1987) (0)
AND CENTRAL CHOLINERGIC FUNCTION (1990) (0)
Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease? (2022) (0)
819 – STUDIES ON THE MECHANISM OF THE EFFECT OF INHIBITORS OF DOPAMINE B HYDROXYLASE ON THE L-DOPA REVERSAL OF RESERPINE AKINESIA (1977) (0)
Excitatory Amino Acids (1987) (0)
OBSERVATIONS ON CHLORALOSE-INDUCED GUINEA-PIGS MYOCLONUS (1980) (0)
The Neurobiology of Gangliosides (1986) (0)
2.249 Investigation on the prevalence of dyskinesia following the switch from pulsatile rotigotine or L-DOPA to continuous rotigotine (2007) (0)
Early monoaminergic dysfunction. (1992) (0)
Dopamine D-1, D-2 and D-3 receptor binding density was not altered in tetrahydrobiopterin-deficient hph-1 mice (2001) (0)
Chronic trifluoperazine administration alters the perioral movement profile in wistar but not sprague-dawley rats (1990) (0)
EFFECT OF EXPERIMENTAL-ISCHEMIA ON CEREBRAL MONO-AMINE LEVELS IN GERBIL BRAIN (1978) (0)
Disorders of Sleep and Wakefulness (1987) (0)
ALTERATIONS IN IRON CONTENT IN PARKINSONIAN BRAIN (1988) (0)
Dysregulation of epithelial ion transport and neurochemical changes in the colon of a parkinsonian primate (2021) (0)
IV.2 Future symptomatic treatments of Parkinson's Disease (2006) (0)
Drug Treatment of Infections of the Nervous System (1987) (0)
Symptomatic and neuroprotective effects of dopamine agonists in Parkinson's disease (1998) (0)
Chronic amphetamine administration and central dopamine receptor sensitivity [proceedings]. (1977) (0)
Central dopaminergic and noradrenergic components of bromocryptine-induced locomotor activity in mice [proceedings]. (1977) (0)
Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats (2014) (0)
Alterations in GABA(B)1B and GABA(B)1C receptor gene expression in the basal ganglia and thalamus of rats bearing A nigrostriatal tract lesion (2001) (0)
Headache, Pain and Raised Intracranial Pressure (1987) (0)
Neuronal Compensation and Age as Factors Affecting MPTP-induced Parkinsonism in the Common Marmoset (1988) (0)
Chronic administration of bts 74 398 does not induce abnormal movements in 6-OHDA lesioned rats [Abstract] (2003) (0)
Increase in the number of striatal neuronal nitric oxide synthase immunoreactive (nNOS-ir) interneurones in MPTP-treated common marmosets primed for and displaying levodopa-induced dyskinesia (2013) (0)
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates (2005) (0)
DIFFERENT EFFECTS OF ANTI-CONVULSANT DRUGS ON PLASMA TRYPTOPHAN LEVELS IN EPILEPTIC PATIENTS (1983) (0)
Chapter 15 – Novel Therapeutic Approaches to the Treatment of Parkinson's Disease (2005) (0)
Brain Receptor Methodologies. Part A General Methods and Concepts, Amines and Acetycholine. Part B Amino Acids, Peptides, Psychoactive Drugs (1985) (0)
Effect of cytochrome P4502E1 inhibition on free radical formation and dopamine efflux in the rat stratum: A microdialysis study (2001) (0)
Differential effects of ropinirole, bromocriptine and L-DOPA on striatal preprodynorphin mrna expression in the MPTP-treated marmoset (1999) (0)
The effect of carbidopa on the phannacokinetics of L-dihydroxyphenylalanine in the rat (1990) (0)
Stereoselective blockade of cerebral dopamine receptors by sulpiride and sultopride [proceedings]. (1979) (0)
ラット線条体試料に対する[3H]スルピリドの特異的結合 (1979) (0)
Symposium of Plant and the Central Nervous System (CNS), September 9: Plants as toxins, tools and therapeutic agents in the CNS (1998) (0)
The antiparkinsonian activity of L-Propyl-L-Leucyl-Glycinamide (PLG) or Melanocyte-Inhibiting Factor (MIF) in MPTP-treated common marmosets (2006) (0)
Selective Actions of Substituted Benzamide Drugs on Brain Dopamine Receptors (1985) (0)
1-methyl-4-phenyl-1,2,3,6-tetradropyridine-induced parkinsonism in the commonmarmoset (1984) (0)
Enhanced GABA function in the angular complex (lateral periaqueductal grey matter and adjacent reticular formation) alters the postural component of striatal- or nigral-derived circling (2004) (0)
Erratum to: Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture (2013) (0)
Vitamins and the Nervous System (1987) (0)
Theinteraction ofsubstituted benzamides withbrain benzodiazepine binding sites invitro (1988) (0)
Prolonged elevation of PPE-A and PPT mRNA following chronic L-DOPA treatment of 6-OHDA lesioned rats (2001) (0)
1564 Adenosine A2α antagonists are antiparkinsonian in MPTP treated primates (1997) (0)
Role of Dopamine Receptor Subtypes in the Treatment of Parkinson's Disease and Induction of Dyskinesia (1997) (0)
Letter to the editor (1997) (0)
Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease (2021) (0)
Receptors and Ligands in Psychiatry. Intercellular and Intracellular Communication series Vol 3 (1989) (0)
Contractile dysfunction and nitrergic dysregulation in small intestine of a primate model of Parkinson’s disease (2019) (0)
Unexpected findings of study of selegiline have not been treated with caution its authors advised (1997) (0)
Cellular and Molecular Basis of Cholinergic Function. (Ellis Horwood Series in Biomedicine.) (1988) (0)
M Journal of Neural Transmission Synergism of the Ampa-antagonist Nbqx and the Nmda-antagonist Cpp with L-dopa in Models of Parkinson's Disease (0)
A.2 The preclinical profile of rotigotine (Neupro®), a novel non-ergolinic dopamine agonist for the transdermal treatment of Parkinson's Disease (2006) (0)
Immunosuppressant and Cytotoxic Drugs, Toxic and Metabolic Disorders (1987) (0)
Alpha‐tocopherol levels in Parkinsonian brains (1993) (0)
Continuous vs pulsatile administration of rotigotine in rat and monkey models of Parkinson's disease: A comparison (2008) (0)
Treatment of the later stages of Parkinson’s disease – pharmacological approaches now and in the future (2015) (0)
A 77636, A DOPAMINE (DA) D‐1 RECEPTOR AGONIST WITH EFFICACY IN THE MPTP MARMOSET MODEL OF PARKINSONISM. (1992) (0)
P3.107 Expression of Integrins αv, β3, β1 and CD44 receptor may explain the neuroprotective effects of osteopontin (2009) (0)
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals. (2023) (0)
Reversal of Pharmacological and Biochemical Effects of Neuroleptic Drugs on Chronic Administration (1980) (0)
Introduction: agonizing over agonists (2003) (0)
Evaluation of the physico-chemical and biological properties of the proteasomal inhibitor PSI (2010) (0)
A glimmer of light at the end of the tunnel? (2017) (0)
Neurodegenerative diseases and clues to their cause provided by plant toxins (1998) (0)
Deprenyl inthemanagementofresponsefluctuations inpatients withParkinson's disease on levodopa (1980) (0)
Animal Models of Movement Disorders (2017) (0)
Treatment of Disorders Involving the Autonomic Nervous System (1987) (0)
Lack of serotoninergic involvement in turning behaviour induced by a unilateral lesion of the locus coeruleus in rats [proceedings]. (1977) (0)
Factors affecting reproducibility of proteasomal inhibition following PSI systemic administration to experimental animals (2013) (0)
Interpretation of radioactive ligand binding to cerebral dopamine receptors (1981) (0)
820 – NORADRENALINE AS A DETERMINANT OF MOTOR ACTIVITY IN LEVODOPA REVERSAL OF DRUG-INDUCED AKINESIA (1977) (0)
P2.120 iNOS-but not nNOS-inhibition protects against 6-OHDA-induced nigral cell loss in an animal model of PD (2009) (0)
The effect of unilateral pallidotomy on motor disability, and L-dopa-induced dyskinesia in parkinsonian marmosets (2002) (0)
A-86929: A selective dopamine D1 receptor agonist with anti-Parkinsonian efficacy in MPTP-lesioned primate models (1995) (0)
ON THE MECHANISMS OF EXTRAPYRAMIDAL REACTIONS INDUCED BY NEUROLEPTIC DRUGS (1979) (0)
Drugs in Neuroendocrinology (1987) (0)
Neurotransmitters and the Cerebral Circulation. (DERS Monograph Series, Volume 2). (1985) (0)
2545 – APPARENT DOPAMINE RECEPTOR BLOCKADE BY SUBSTITUTED BENZAMIDE DRUGS (1978) (0)
Alterations in striatal preprotachykinin and nigral tyrosine hydroxylase mrna in tetrahydrobiopterin-deficient mice (1997) (0)
Proceedings: Reduction of locomotor activity in mice by dopamine-beta-hydroxylase inhibitors--evidence against the involvement of non-specific irritation. (1976) (0)
A late appearance by the dopamine D‐3 receptor (2014) (0)
Localisation of caspases in the substantia nigra of the rat brain. (2000) (0)
Proteomic Analysis of Striatum from MPTP-Treated Marmosets (Callithrix jacchus) with l-DOPA-Induced Dyskinesia of Differing Severity (2013) (0)
Dementia with Lewy Bodies: Relevance of Lewy bodies to alterations in oxidative stress in Lewy body dementia and Parkinson's disease (1996) (0)
Introduction. (2020) (0)
Chronic L-DOPA treatment decreases striatal cannabinoid CB-1 mRNA expression in MPTP-treated marmosets (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Peter G. Jenner?

Peter G. Jenner is affiliated with the following schools:

Peter G. Jenner's Academic­Influence.com Rankings

Why Is Peter G. Jenner Influential?

Peter G. Jenner's Published Works

Published Works

What Schools Are Affiliated With Peter G. Jenner?

Peter G. Jenner's AcademicInfluence.com Rankings